Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa

Current Opinion in HIV and AIDS

Volumn 8, Issue 1, 2013, Pages 19-26

  Hamers, Raph L ^a   Sigaloff, Kim C E ^a   Kityo, Cissy ^b   Mugyenyi, Peter ^b   De Wit, Tobias F Rinke ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b JOINT CLINICAL RESEARCH CENTRE   (Uganda)

Author keywords

antiretroviral therapy; drug resistance; HIV 1; review; sub Saharan Africa

Indexed keywords

EFAVIRENZ; NEVIRAPINE; RITONAVIR;

ACQUIRED DRUG RESISTANCE; AFRICA; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; DRUG RESPONSE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TRANSMITTED DRUG RESISTANCE; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS REPLICATION;

AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS;

EID: 84871921929     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32835b7f94     Document Type: Review

References (78)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. http://www.unaids.org/globalreport/global-report.htm [Accessed 15 July 2012].
2. WHO, UNAIDS, UNICEF. Global HIV/AIDS response: epidemic update and health sector progress towards Universal Access: progress report 2011. http://www.who.int/hiv/pub/progress-report2011/hiv-full-report-2011.pdf [Accessed 15 July 2012].
3. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 rev. http://www.who. int/hiv/pub/guidelines/adult/en/index.html [Accessed 15 July 2012].
4. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-31.
5. Pasquet A, Messou E, Gabillard D, et al. Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Cô te d'Ivoire. PloS One 2010; 5:e13414.
6. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine-and efavirenz-based antiretroviral therapy when coadministered with rifampicinbased antitubercular therapy. J Am Med Assoc 2008; 300:530-539.
7. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. The N Engl J Med 2011; 365:637-646.
8. Wood E, Montaner JS. Time to get serious about HIV antiretroviral resistance. Lancet Infect Dis 2011; 11:723-724.
9. WHO. WHO HIV Drug Resistance Report 2012. http://www.who.int/mediacentre/ news/notes/2012/hiv-drug-resistance-20120718/en/index.html [Accessed 1 August 2012].
10. Somda A, Sangare L, Soro M, et al. Surveillance of transmitted drug-resistant HIV among young pregnant women in Ouagadougou, Burkina Faso. Clin Infect Dis 2012; 54 (Suppl 4):S317-S319.
11. Hunt GM, Ledwaba J, Basson AE, et al. Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009. Clin Infect Dis 2012; 54 (Suppl 4):S334-S338.
12. Ndembi N, Hamers RL, Sigaloff KC, et al. Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS 2011; 25:905-910.
13. Sigaloff KC, Mandaliya K, Hamers RL, et al. High prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya. AIDS Res Hum Retroviruses 2012; 28:833-837.
14. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviralnaive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750-759.
15. Aghokeng AF, Kouanfack C, Laurent C, et al. Scale-up of antiretroviral treatment in Cameroon is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS 2011; 25:2183-2188.
16. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and metaregression analysis. Lancet 2012; 380:1250-1258.
17. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach 2010 version. http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index. html [Accessed 25 January 2012].
18. DHHS. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo. nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [Accessed 17 July 2012].
19. WHO. The strategic use of antiretrovirals to help end the HIV epidemic
20. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
21. Hamers RL, Schuurman R, Sigaloff KC. Effect of pretreatment HIV-1 drugresistance on immunological, virological and drug-resistance outcomes of first-line antiretroviral treatment: multicentre cohort in six African countries. Lancet Infect Dis 2012; 12:307-317.
22. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11:363-371.
23. Li JZ, Paredes R, Ribaudo HJ, et al. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 2012; 26:185-192.
24. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. J Am Med Assoc 2011; 305: 1327-1335.
25. Hunt GM, Coovadia A, Abrams EJ, et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS 2011; 25:1461-1469.
26. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012; 366: 2368-2379.
27. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366:2380-2389.
28. Penazzato M, Prendergast A, Tierney J, et al. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Cochrane Database Syst Rev 2012; 7:CD004772.
29. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13 (Suppl 2):1-13. (Pubitemid 352019085)
30. Bennett DE, Jordan MR, Bertagnolio S, et al. HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis 2012; 54 (Suppl 4):S280-S289.
31. Jordan MR, Bennett DE, Bertagnolio S, et al. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13 (Suppl 2):15-23. (Pubitemid 352019086)
32. Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012; 54:1660-1669.
33. Wallis CL, Papathanasopoulos M, Fox MP, et al. Low rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance detected in a well monitored cohort in South Africa accessing antiretroviral therapy. Antivir Ther 2012; 17:313-320.
34. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25:679-689.
35. Coutsinos D, Invernizzi CF, Xu H, et al. Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antivir Chem Chemother 2010; 20:117-131.
36. Coutsinos D, Invernizzi CF, Xu H, et al. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 2009; 83:2029-2033.
37. Wallis CL, Mellors JW, Venter WD, et al. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-484.
38. van Zyl GU, van der Merwe L, Claassen M, et al. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. J Med Virol 2011; 83:1764-1769.
39. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8:477-489. (Pubitemid 352005822)
40. Sigaloff KC, Calis JC, Geelen SP, et al. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis 2011; 11:769-779.
41. Frange P, Briand N, Avettand-fenoel V, et al. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure. Pediatric Infect Dis J 2011; 30:684-688.
42. van Zyl GU, van der Merwe L, Claassen M, et al. Protease inhibitor resistance in South African children with virologic failure. Pediatric Infect Dis J 2009; 28:1125-1127.
43. Taylor BS, Hunt G, Abrams EJ, et al. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses 2011; 27:945-956.
44. Barth RE, Tempelman HA, Smelt E, et al. Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on first-line treatment. Pediatric Infect Dis J 2011; 30: 52-56.
45. Barth RE, Aitken SC, Tempelman H, et al. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Antivir Ther 2012; 17:377-386.
46. Westley BP, Delong AK, Tray CS, et al. Prediction of treatment failure using 2010 World Health Organization guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children. Clin Infect Dis 2012; 55:432-440.
47. Schneider K, Puthanakit T, Kerr S, et al. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings. AIDS 2011; 25:1143-1151.
48. Hosseinipour MC, Kumwenda JJ, Weigel R, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 2010; 11:510-518.
49. Sigaloff KC, Hamers RL, Wallis CL. Second-line antiretroviral treatment successfully re-suppresses drug-resistant HIV-1 after first-line failure: prospective cohort in sub-Saharan Africa. J Infect Dis 2012; 205:1739-1744.
50. Bartlett JA, Ribaudo HJ, Wallis CL, et al. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS 2012; 26:1345-1354.
51. Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy vs. tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI-regimens: the HIV STAR study. Antivir Ther 2012 [Epub ahead of print]. doi:10.3851/IMP2222.
52. Ajose O, Mookerjee S, Mills EJ, et al. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS 2012; 26:929-938.
53. Zyl GU, Rabie H, Nuttall JJ, Cotton MF. It is time to consider third-line options in antiretroviral-experienced paediatric patients? J Int AIDS Soc 2011; 14:55.
54. Fokam J, Salpini R, Santoro MM, et al. Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. Pediatric Infect Dis J 2011; 30:1062-1068.
55. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-434.
56. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367: 399-410.
57. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-422.
58. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
59. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
60. Supervie V, Barrett M, Kahn JS, et al. Modeling dynamic interactions between preexposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance. Sci Rep 2011; 1:185.
61. Dolling D, Phillips AN, Delpech V, et al. Evaluating the extent of potential resistance to preexposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med 2012; 13:309-314.
62. Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral preexposure prophylaxis (PrEP). PloS One 2011; 6:e18165.
63. Parikh UM, Mellors JW. HIV-1 drug resistance resulting from antiretroviral therapy far exceeds that from preexposure prophylaxis. Clin Infect Dis 2012; 55:303-304.
64. Jourdain G, Ngo-Giang-Huong N, Le CS, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240. (Pubitemid 38922817)
65. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15:1951-1957. (Pubitemid 32980636)
66. Micek MA, Blanco AJ, Carlsson J, et al. Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine. J Infect Dis 2012; 205:1811-1815.
67. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-180.
68. Group TKBS. Maternal HIV-1 disease progression 18-24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): the Kesho Bora randomized controlled trial. Clin Infect Dis 2012; 55:449-460.
69. Souda S, Gaseitsiwe S, Georgette N, et al. No clinically significant drug resistance mutations in HIV-1 subtype c-infected women after discontinuation of protease inhibitor-based or NRTI-based HAART for PMTCT. 19th Conference on Retroviruses and Opportunistic Infections; Seattle, Washington, USA; 5-8 March 2012 [Abstract #1018].
70. WHO. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Programmatic update 2012. http://www.who.int/hiv/pub/mtct/programmatic-update2012/en/index.html [Accessed 1 August 2012].
71. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
72. Hamers RL, Sawyer AW, Tuohy M, et al. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 2012; 26:1663-1672.
73. Phillips AN, Pillay D, Garnett G, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS 2011; 25:843-850.
74. Parkin N, Bremer J, Bertagnolio S. Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010. Clin Infect Dis 2012; 54 (Suppl 4):S266-S272.
75. Rosen S, Long L, Sanne I, et al. The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc 2011; 14:24.
76. Parkin N, de Mendoza C, Schuurman R, et al. Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network. Clin Infect Dis 2012; 54 (Suppl 4):S273-S279.
77. Aitken SC, Wallis CL, Stevens W, et al. Effect of storage conditions on the detection of HIV-1 minority viral populations in DBS using population-based genotyping [Abstract #741]. 19th Conference on Retroviruses and Opportunistic Infections; Seattle, Washington, USA; 5-8 March 2012. [Abstract #741].
78. Ziemniak C, Mengistu Y, Ruff A, et al. Use of dried-blood-spot samples and inhouse assays to identify antiretroviral drug resistance in HIV-infected children in resource-constrained settings. J Clin Microbiol 2011; 49:4077-4082.